Korean study tracks new psoriasis Treatment's Real-World safety

NCT ID NCT06886009

Summary

This study aims to monitor the safety and effectiveness of spesolimab, an intravenous medication, in Korean patients experiencing severe flares of generalized pustular psoriasis. Researchers will observe 21 patients in routine medical practice to track side effects and how well the treatment clears skin pustules. The study focuses on real-world use after the medication's approval in Korea.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED PUSTULAR PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ajou University Hospital

    Suwon, 16499, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Asan Medical Center

    Seoul, 05505, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Pusan National University Yangsan Hospital

    Busan, 49241, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Samsung Medical Center

    Seoul, 06351, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.